Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pressure Builds For Biosimilars To Follow Lilly’s Lead After Insulin Price Cap

Eli Lilly Will Bear The Cost Of A $35 Price Cap On All Copays For Its Insulins

Executive Summary

Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.

You may also be interested in...



Meitheal Looks To Chinese Parent To Bring In Three US Insulin Biosimilars

Designed as its US commercial arm following a major investment four years ago, Chinese player Nanjing King-Friend Biochemical Pharmaceutical has signed a deal allowing Meitheal Pharmaceuticals to sell three insulin biosimilars in the US.

IRA Drug Pricing Implications Impact Pharma Views On Deal Terms, Valuations

Pharma business development executives and venture capital investors shared their thoughts on the Inflation Reduction Act at Biocom’s Global Life Science Partnering and Investor Conference in San Diego.

Lilly’s Insulin Cost Cutting Plan: Replacing Rebates With Cost Sharing Help At Point Of Sale

Biden Administration praises Lilly for latest moves to improve affordability of insulin in private market and calls for other sponsors to follow suit. Lilly’s plan is also tactical, as manufacturers of highly-rebated drugs with serial price hikes face an increased rebate liability in Medicaid next year.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel